According to a study presented at the 2011 European Multidisciplinary Cancer Congress, children born to women who received chemotherapy during pregnancy do not appear to have an increased risk of heart or cognitive problems. Since relatively few women are diagnosed with cancer during pregnancy, data regarding the effects of chemotherapy during pregnancy are limited. Determining [...]
A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals of Surgery. Clinical trials are the process through which medications ultimately become approved by the [...]
The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of [...]
Among patients with follicular lymphoma who responded to initial treatment with chemotherapy and Rituxan® (rituximab), those who received an additional two years of Rituxan as maintenance therapy remained free of lymphoma progression for longer than patients who did not receive maintenance therapy. These results were published in the The Lancet. Rituxan is a targeted therapy [...]
Compared with a watchful-waiting strategy, treatment with Rituxan® (rituximab) appears to delay the need for chemotherapy among patients with Stage II-IV, asymptomatic, non-bulky follicular lymphoma. These preliminary results were presented at the 52nd annual meeting of the American Society of Hematology (ASH). Follicular lymphoma is an indolent (slow-growing) type of non-Hodgkin’s lymphoma. It involves a [...]
Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology. Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin’s lymphoma that begins in the skin. The most common type of CTCL is mycosis [...]
Individuals with chronic hepatitis B virus (HBV) infection may have an increased risk of developing non-Hodgkin’s lymphoma (NHL), according to findings recently published in The Lancet Oncology. Hepatitis B is a virus that causes inflammation of the liver. It is spread through contact with body fluids and can be transmitted through blood, sexual contact, or [...]
In 2008, excess body weight was responsible for over 124,000 new cancer diagnoses in Europe. These results were presented at a major European cancer conference. Obesity is increasingly being recognized as a risk factor not only for cancer development, but also for worse outcomes after cancer treatment. Links between obesity and endometrial cancer, postmenopausal breast [...]
Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.[1] Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. It is characterized by excessive accumulation of cancerous lymphocytes, which can crowd [...]
Among patients with a type of T-cell non-Hodgkin’s lymphoma known as angioimmunoblastic T-cell lymphoma (AITL), treatment with allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients. The results of this study were published in the Journal of Clinical Oncology. T-cell lymphomas are a relatively uncommon form of non-Hodgkin’s lymphoma (NHL) [...]
